Ravi Parikh, MD MPH

Physician. Retina Specialist. Public Health/Policy Advocate. Chairman @ManhattanRetinaEye, Faculty @OrbisIntl, @NYULangone, Trained @Harvard, @Yale, @Vanderbilt

[Ravi Parikh, MD MPH @RaviParikhMD]

Thank you so much to all collaborators, colleagues and friends The @nyuniversity @nyulangone @NYULangoneEye and @nyugrossman has been a great community to collaborate with. #MedTwitter @RealWorldOphth

[NYU Langone Ophthalmology @NYULangoneEye]

Congratulations to Clinical Assistant Professor Dr. Ravi Parikh @RaviParikhMD for being awarded the @RealWorldOphth RWO Visionary Award! This honor is given to young ophthalmologists whose work demonstrates qualities of exceptional foresight, creativity, advocacy, & vision.

[Ravi Parikh, MD MPH @RaviParikhMD]

@US_FDA @FDArecalls @eyeadvocacy #publichealth
#eyetwitter @DGlaucomflecken

[Ravi Parikh, MD MPH @RaviParikhMD]

🚨Recall alert over 3 million eyedrops recalled possibly having sterility issues. Recent years have seen major health issues from contaminated drops. 🚨

This @USATODAY article does a great job showing which ones to avoid. Check your drops!
https://t.co/lFcRLCpf9n

[Ravi Parikh, MD MPH @RaviParikhMD]

3 of 3

Thanks to everyone involved @NYULangoneEye and @ShileyEye

#ophthotwitter, #diabetes , #AMD , #maculardegeneration

[Ravi Parikh, MD MPH @RaviParikhMD]

First research publication of the new year ! (1 of 3)

In the US for retinal diseases #vabysmo has the highest rate of absolute and relative increase in adoption while #eylea is the most commonly used drug. Lower cost avastin is declining

https://t.co/LQMGvWIicl

#medtwitter

[Ravi Parikh, MD MPH @RaviParikhMD]

2 of 3
We also found those with Medicare b or c much more likely than Medicaid or commercial patients to receive higher cost drugs, showing a potential access issue due to step therapy , #prior-authorization, etc that many insurers use.

[Ravi Parikh, MD MPH @RaviParikhMD]

@npunwani @chamath Great points !

[Ravi Parikh, MD MPH @RaviParikhMD]

The most commonly done surgical procedure in #ophthalmology and #medicine are intravitreal injections

Thanks ⁦@medpagetoday⁩ for having me comment on the #malpractice and legal issues around these sight saving procedures ⁦@aao_ophth⁩ https://t.co/EVkgMPzXtA

[Ravi Parikh, MD MPH @RaviParikhMD]

For #nyc and other big races make sure you #vote today

[Ravi Parikh, MD MPH @RaviParikhMD]

we published that #AI screening for diabetic eye disease has the potential to bring many people into care and reduce disparities, but we found that many centers did not offer or even know if they offered such services along with long wait times to physicians

[Ravi Parikh, MD MPH @RaviParikhMD]

Our latest study presented #aao2025 in Orlando, Florida looked at patient access to #AI, general medical, eye, and #telemedicine for diabetic retinopathy.

1 of 2

[Ravi Parikh, MD MPH @RaviParikhMD]

Happy Diwali 🪔

[Ravi Parikh, MD MPH @RaviParikhMD]

#NeverForget911

Prayers for a safer, more inclusive, and better understanding world for us all.

🙏🏾

[Ravi Parikh, MD MPH @RaviParikhMD]

Honored to receive the distinguished young physician’s award from @AAPIUSA and meet such distinguished physician leaders like @ashishkjha @AmerMedicalAssn @PresAmerMed Bobby Mukkamala and Nageswar Reddy chief of @AIGHospitals #Gi dept

[Ravi Parikh, MD MPH @RaviParikhMD]

Bring on the #paris #heatwave with an iconic and international @maculart meeting

We presented our worlds first #GA (geographic atrophy) calculator for #dryamd

https://t.co/jflefhRNcr

Thanks to all involved for a great meeting!!! #retina #MedTwitter

[Ravi Parikh, MD MPH @RaviParikhMD]

Just landed back home from a presentation abroad in Paris and then to Oslo. No better place to live (yes there are many things to improve on still) than the United States of America 🇺🇸; happy bday America!!! #fourthofjuly2025

[Ravi Parikh, MD MPH @RaviParikhMD]

Honored to be named in the top 1% of Ophthalmology Researchers despite spending most of my time seeing patients

It’s important to do work you feel is meaningful, are interested in, and may benefit individual patients as well as the field/community at large.

[Ravi Parikh, MD MPH @RaviParikhMD]

Such as those wirh #sicklecell #radiation retinopathy neovascularization from #uveitis and many more conditions

[Ravi Parikh, MD MPH @RaviParikhMD]

Thanks @aao_ophth and @AAOjournal for allowing us to highlight the need for access to #avastin which is both low cost and effective for many pts with neovascular retinal diseases.

Restriction of repackaged avastin would jeopardize access for 1 in 5 retina pts

[Ophthalmology @AAOjournal]

Anti-VEGF Use for Conditions without Food and Drug Administration Approval
https://t.co/wSjANEAEo0
@raviparikhmd
#ophthalmology #retina

[Ravi Parikh, MD MPH @RaviParikhMD]

In #urgentcare visits #AI alone performed better with less potentially dangerous decisions and more optimal quality decisions than a #physician with #AI assistance.

Will we accept #AI only for urgent care especially as it will never be perfect ?

https://t.co/mM1i17xaKF

[Ravi Parikh, MD MPH @RaviParikhMD]

Thanks to all coauthors and collaborators ! Thanks to @aao_ophth for allowing use of the #iris #registry

[Ravi Parikh, MD MPH @RaviParikhMD]

are #antivegf #retina drugs use for non-@US_FDA approved indications ie not #AMD or #diabetes etc?

Our study in @aaojournal #retina shows quite a few, underscoring the importance of low cost options and insurer coverage of higher cost ones

https://t.co/x89crrhI3a